Evaluation of the prophylactic effect of magnesium sulfate on cerebral Vasospasm in Subarachnoid hemorrhage

Evaluation of the prophylactic effect of magnesium sulfate on cerebral vasospasm in subarachnoid hemorrhage in moderate and severe brain trauma using with transcranial doppler

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221023056270N1

Enrollment

Registered

2025-07-18

Start date

2025-08-14

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sub arachnoid hemorrage. I60.1Subarachnoid Hemorrhage from middle cerebral artery I60.2Subarachnoid Hemorrhage from anterior communicating arteryI60.3Subarachnoid haemorrhage from posterior communicating artery

Interventions

Intervention 1: Intervention group: Patients with moderate and severe brain trauma who received intravenous magnesium sulfate. Intervention 2: Control group: People with moderate or severe brain traum

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with moderate (GCS9-13) and severe (GCS3-8) brain trauma Fisher grade2-3 Absence of renal failure Stable vital signs

Exclusion criteria

Exclusion criteria: Patients with mild brain trauma (GCS14-15) Fisher grading1 or4 Patients with unstable vital signs or imminent death, patients with kidney failure (Cr>1.4) Patients with heart disease (second degree heart block, severe valve stenosis, Hypertrophic obstructive cardiomyopathy, EF<30%)

Design outcomes

Primary

Measure	Time frame
The amount of cerebrovascular Vasospasm based on blood flow velocity above 120cm/s in Trans Cranial Doppler. Timepoint: Measurement of Vasospasm on days 7, 14, 21 after administering magnesium sulfate intravenously. Method of measurement: Blood flow velocity usingTranscranial Doppler.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactReza Bahrami Ilkhchi

Tabriz University of Medical Sciences

rbahrami1400@gmail.com+98 41 3334 0830

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026